On March 25, the closing price of Jincheng Pharm (300233.SZ) was reported at 21.76 yuan, a significant increase of 3.63 yuan compared to the previous trading day's closing price of 18.13 yuan, with a percentage increase of 20.02%, hitting the limit up.
Jincheng Pharm opened at 18.75 yuan, with both the highest and closing prices reaching 21.76 yuan and the lowest price at 18.65 yuan. The total trading volume for the day was 759,700 shares, with a turnover of 1.56 billion yuan. By the closing bell, Jincheng Pharm's total market value was 8.353 billion yuan, and its circulating market value was 8.049 billion yuan.
It is worth noting that Jincheng Pharm's current stock price has reached its 52-week high of 21.76 yuan.
According to reports, Jincheng Pharm obtained the Tobacco Monopoly Production Enterprise License in July 2023. In January 2025, the company announced on the investor interaction platform that its nicotine production capacity is 200 tons per year, and monthly production tasks are arranged based on order situations. Currently, nicotine is mainly used in the new tobacco field, and the company is also gradually expanding and developing other related products.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
